glp-1 weight loss monroe in GA Weight Loss - Fast Pace
Description
Articles of all types were included in this review if the inclusion/exclusion criteria were met
Early signs that a dose adjustment might be needed
The US Food and Drug Administration approved this first-in-class medication for the management of type 2 diabetes (T2D) in 2022 [2], for the reduction of excess weight in adults with obesity or overweight in 2023 [3], and for moderate-to-severe obstructive sleep apnea (OSA) in people with obesity in 2024 [4]
CORRECTION (Oct
Clinical trials show tirzepatide may produce greater weight loss for some patients, though both are highly effective
